# Ticagrelor

## Brilinta 90mg

| 藥物代碼 | OBRI |
| :--- | :--- |
| 適應症 | Prevention of atherothrombotic events in patients w/ acute coronary syndromes \(ACS\) \[unstable angina, non-ST elevation MI \(NSTEMI\) or ST elevation MI \(STEMI\)\] including patients managed medically & managed w/ percutaneous coronary intervention \(PCI\) or CABG co-administered w/ acetylsalicylic acid \(ASA\). |
| 副作用 | Dyspnoea, epistaxis, GI haemorrhage, subcutaneous or dermal bleeding, bruising, procedural site haemorrhage. |
| 禁忌 | Active pathological bleeding, history of intracranial haemorrhage, moderate to severe hepatic impairment, co-administration w/ strong CYP3A4 inhibitors. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Acute coronary syndrome \(ACS\): Initially 180 mg single loading dose then continue at 90 mg bid for 12 months. History of MI Co-administered with Aspirin 75-150 mg: 60 mg bid when an extended treatment is required. |
| 肝功能異常 | 需 調 整 劑 量  Moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling \(has not been studied\); however, undergoes hepatic metabolism; use caution. Severe impairment: Avoid use. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

